FindTrial
Sign In

Post-hoc analysis of Myopia progression after discontinuation of Atropine sulfate (DE-127) ophthalmic solution in the Phase II/III clinical trial in Japan

Post-hoc analysis of Myopia progression after discontinuation of Atropine sulfate (DE-127) ophthalmic solution in the Phase II/III clinical trial in Japan - Post-hoc analysis of Myopia progression after discontinuation of Atropine sulfate (DE-127) ophthalmic solution in the Phase II/III clinical trial in Japan

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000058693
Enrollment
211
Registered
2025-08-04
Start date
2025-08-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Interventions

None listed

Sponsors

Santen Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: None

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Changes in SE and AL by subject characteristics Proportion of categories of annual changes in SE and AL Examination of subject characteristic factors associated with changes in SE and AL—

Countries

Japan

Contacts

Public ContactEtsuyo Miyamoto

Santen Pharmaceutical Co., Ltd. Japan Medical Affairs Group

clinical@santen.co.jp06-4802-9337

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026